Sara Tolaney Harvard
Interviews and expert commentary tagged “Sara Tolaney Harvard” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Audio Journal of Oncology
Rebecca Dent MD: First-Line T-DXd Combination Adds More Than a Year of Progression Free Survival for Patients with Advanced HER2 Positive Breast Cancer
Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+
25 July 2025
0:00